These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29791559)

  • 1. Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    J Bras Pneumol; 2018 Apr; 44(2):85-92. PubMed ID: 29791559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
    Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
    Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
    Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
    Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of auditory evoked potentials and otoacoustic emissions in early detection of hearing abnormalities in Behçet's disease patients. A case control study.
    Nada DW; El Khouly RM; Gadow SE; Hablas SA; Aboelhawa MA; Al Ashkar DS; El Barbary AM; Hussein MS; Rageh E; Elsalawy AM; Abo-Zaid MH; Elshweikh S; El Gharib AM
    Clin Exp Rheumatol; 2018; 36(6 Suppl 115):45-52. PubMed ID: 29745880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
    McMillan GP; Konrad-Martin D; Dille MF
    Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.
    Appana D; Joseph L; Paken J
    S Afr J Commun Disord; 2016 Nov; 63(1):e1-e12. PubMed ID: 28155306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early hearing threshold changes and peculiarities of audiometric assessments among patients in a drug-resistant tuberculosis treatment center.
    Sogebi OA; Adefuye BO; Ajayi EA
    Afr Health Sci; 2021 Mar; 21(1):230-237. PubMed ID: 34394302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.
    Modongo C; Sobota RS; Kesenogile B; Ncube R; Sirugo G; Williams SM; Zetola NM
    BMC Infect Dis; 2014 Oct; 14():542. PubMed ID: 25300708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
    Md Daud MK; Mohamadl H; Haron A; Rahman NA
    B-ENT; 2014; 10(1):53-8. PubMed ID: 24765829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.
    Modongo C; Pasipanodya JG; Zetola NM; Williams SM; Sirugo G; Gumbo T
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6337-43. PubMed ID: 26248372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations.
    Sogebi OA; Fadeyi MO; Adefuye BO; Soyinka FO
    J Bras Pneumol; 2017; 43(3):195-201. PubMed ID: 28746530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity.
    Hotz MA; Harris FP; Probst R
    Laryngoscope; 1994 Sep; 104(9):1130-4. PubMed ID: 8072361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
    Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
    BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test-retest reliability of distortion-product thresholds compared to behavioral auditory thresholds.
    Bader K; Dierkes L; Braun LH; Gummer AW; Dalhoff E; Zelle D
    Hear Res; 2021 Jul; 406():108232. PubMed ID: 33984603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
    Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
    Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB).
    Sabur NF; Brar MS; Wu L; Brode SK
    BMC Infect Dis; 2021 Mar; 21(1):254. PubMed ID: 33691624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.